Although several PARP inhibitors have been approved for the treatment of breast and/or ovarian cancers with BRCA mutations, like other targeted therapies, those patients who showed initial response to PARP-i often develop resistance, and relapsed disease is commonly observed. The gene discussed is PARP1; the disease is ovarian cancer.